Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, Charpentier MC, Bain S, Marmey B, Bonjour P, Biton J, Cremer I, Dieu-Nosjean MC, Sautès-Fridman C, Régnard JF, Laurent-Puig P, Alifano M, Damotte D. Mansuet-Lupo A, et al. Among authors: biton j. Chest. 2014 Sep;146(3):633-643. doi: 10.1378/chest.13-2499. Chest. 2014. PMID: 24676429
Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.
Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Régnard JF, Cremer I, Laurent-Puig P, Dieu-Nosjean MC, Blons H, Damotte D. Mansuet-Lupo A, et al. Among authors: biton j. Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412. doi: 10.1164/rccm.201510-2031OC. Am J Respir Crit Care Med. 2016. PMID: 27299180
Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer.
Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, Goc J, Biton J, Ouakrim H, Cremer I, Dieu-Nosjean MC, Damotte D. Alifano M, et al. Among authors: biton j. PLoS One. 2014 Sep 19;9(9):e106914. doi: 10.1371/journal.pone.0106914. eCollection 2014. PLoS One. 2014. PMID: 25238252 Free PMC article.
Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I. Fucikova J, et al. Among authors: biton j. Cancer Res. 2016 Apr 1;76(7):1746-56. doi: 10.1158/0008-5472.CAN-15-1142. Epub 2016 Feb 3. Cancer Res. 2016. PMID: 26842877
Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D. Biton J, et al. Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC. Am J Respir Crit Care Med. 2018. PMID: 29518341
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.
Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D. Biton J, et al. Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15. Clin Cancer Res. 2018. PMID: 29764856
Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.
Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, Le Hay C, Cremer I, Régnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, Blons H. Mansuet-Lupo A, et al. Among authors: biton j. J Thorac Oncol. 2019 May;14(5):844-856. doi: 10.1016/j.jtho.2019.01.017. Epub 2019 Feb 2. J Thorac Oncol. 2019. PMID: 30721797 Free article.
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
Velut Y, Decroix E, Blons H, Alifano M, Leroy K, Petitprez F, Boni A, Garinet S, Biton J, Cremer I, Wislez M, Boudou-Rouquette P, Arrondeau J, Goldwasser F, Fournel L, Damotte D, Mansuet-Lupo A. Velut Y, et al. Among authors: biton j. Lung Cancer. 2022 Jul;169:13-21. doi: 10.1016/j.lungcan.2022.05.001. Epub 2022 May 5. Lung Cancer. 2022. PMID: 35597058
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K. Damotte D, et al. Among authors: biton j. J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3. J Transl Med. 2019. PMID: 31684954 Free PMC article.
38 results